Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A Meta-Analysis

Abstract Background To evaluate the effects of intravitreal silicone oil (SO) on the retinal and choroidal thickness in eyes with rhegmatogenous retinal detachment (RRD). Methods A literature search was performed in Web of Science, Scopus, ProQuest, Embase, Clinical Key, Science Direct, Cochrane Library, and Springer, as well as Persian databases, including IranDoc, MagIran, SID, MOH thesis, and MOH articles until June 2020. Two reviewers independently searched and extracted the data. Results Sixteen studies (n = 391) met the inclusion criteria. The meta-analysis showed that the SO tamponade could significantly reduce the central macular thickness (CMT) in patients with RRD as compared to gas tamponade WMD = − 14.91; 95% CI: − 22.23, − 7.60; P < 0.001, I2 = 71%). No significant change was found in CMT between the eye with SO tamponade (after SO removal) and the fellow healthy eye in patients with RRD (WMD = − 3.52; 95% CI: − 17.63, 10.59; I2 = 68.6%). Compared to the preoperative stage, the SO tamponade could significantly reduce the subfoveal choroidal thickness in patients with RRD (WMD = − 18.67, 95% CI: − 30.07, − 1.28; I2 = 80.1%). However, there was no significant difference in the subfoveal choroidal thickness before and after SO removal (WMD = − 1.13, 95% CI: − 5.97, 3.71; I2 = 87.6%). Conclusion The SO tamponade had a significant effect on the reduction of retinal layers and the subfoveal choroidal thickness.

Download Full-text

SUBFOVEAL CHOROIDAL THICKNESS IN FELLOW EYES OF PATIENTS WITH CENTRAL SEROUS CHORIORETINOPATHY

Retina ◽

10.1097/iae.0b013e31820f4b39 ◽

2011 ◽

Vol 31 (8) ◽

pp. 1603-1608 ◽

Cited By ~ 177

Author(s):

Ichiro Maruko ◽

Tomohiro Iida ◽

Yukinori Sugano ◽

Akira Ojima ◽

Tetsuju Sekiryu

Keyword(s):

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Subfoveal Choroidal Thickness ◽

Fellow Eyes

Download Full-text

Distinguishing Central Serous Chorioretinopathy From Neovascular Age-Related Macular Degeneration: A Prospective Study

Journal of VitreoRetinal Diseases ◽

10.1177/2474126420914279 ◽

2020 ◽

Vol 4 (4) ◽

pp. 293-299

Author(s):

Parampal S. Grewal ◽

Steven R.J. Lapere ◽

Christopher J. Rudnisky ◽

Rizwan Somani ◽

Matthew T.S. Tennant

Keyword(s):

Decision Making ◽

Macular Degeneration ◽

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Clinical Decision Making ◽

Clinical Decision ◽

Age Related Macular Degeneration ◽

Subfoveal Choroidal Thickness ◽

Pigment Epithelial ◽

Age Related

Purpose: This article identifies clinical features that differentiate central serous chorioretinopathy (CSR) from neovascular age-related macular degeneration (nAMD) and uses this information to develop a diagnostic tool. Methods: A prospective observational study was conducted of patients with a new diagnosis of CSR, nAMD, or indeterminate presentation. All patients underwent clinical assessment, axial length measurement, enhanced-depth imaging–optical coherence tomography, and intravenous fluorescein angiography. A final consensus diagnosis was derived following review of these factors. Results: A total of 56 eyes of 56 patients were enrolled (CSR = 34; nAMD = 22). The subfoveal choroidal thickness was greater in the CSR group (421 ± 106 µm) than the nAMD group (219 ± 91 µm, P < .001). The following odds ratio of CSR reached statistical significance: age 70 and younger (72.00, 95% CI: 11.99-432.50), subfoveal choroidal thickness greater than or equal to 300 µm (33.92, 95% CI: 4.06-283.18), dome-shaped neurosensory detachment (13.24, 95% CI: 3.22-54.45), retinal pigment epithelial changes (0.31, 95% CI: 0.10-0.97), subretinal hyperreflective material (0.11, 95% CI: 0.03-0.42), and fibrovascular pigment epithelial detachment (0.05, 95% CI: 0.01-0.47). A stepwise CSR vs nAMD clinical decision-making algorithm is proposed. Conclusions: Choroidal thickness is increased in CSR when compared with nAMD. The presented odds ratios and the CSR vs nAMD clinical decision-making tool can be applied to distinguish CSR from nAMD.

Download Full-text

Change in subfoveal choroidal thickness in central serous chorioretinopathy

Eye ◽

10.1038/eye.2013.164 ◽

2013 ◽

Vol 27 (10) ◽

pp. 1221-1222 ◽

Cited By ~ 3

Author(s):

C S H Tan ◽

K X Cheong ◽

S R Sadda

Keyword(s):

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Subfoveal Choroidal Thickness

Download Full-text

Subthreshold laser therapy with a standardized macular treatment pattern in chronic central serous chorioretinopathy

Graefe s Archive for Clinical and Experimental Ophthalmology ◽

10.1007/s00417-021-05256-3 ◽

2021 ◽

Author(s):

Benedikt Schworm ◽

Jakob Siedlecki ◽

Leonie F. Keidel ◽

Tina R. Herold ◽

Nikolaus Luft ◽

...

Keyword(s):

Laser Treatment ◽

Central Serous Chorioretinopathy ◽

Choroidal Thickness ◽

Subretinal Fluid ◽

Symptom Duration ◽

Macular Function ◽

Chronic Central Serous Chorioretinopathy ◽

Subfoveal Choroidal Thickness ◽

Laser Treatments ◽

Subthreshold Laser

Abstract Purpose There is an ongoing controversial debate about the effectiveness of laser treatments in chronic central serous chorioretinopathy (cCSC). We performed a prospective non-randomized interventional study to learn about the effects of a subthreshold laser treatment (Topcon Endpoint Management™, Topcon Healthcare Inc., Tokyo, Japan) in patients with cCSC. Methods Patients with cCSC and a minimum symptom duration of 4 months were included and treated with a standardized laser pattern covering the macular area. Retreatment was performed every 3 months if persistent subretinal fluid was observed. The primary endpoint was resolution of subretinal fluid at 6 months. Further outcome parameters included best corrected visual acuity, microperimetry, central macular and subfoveal choroidal thickness. Results A total of 42 eyes of 39 patients were included. Mean patient age was 48 ± 10.6 years (range 25–67). Mean symptomatic time before inclusion into the study was 134 ± 133.4 weeks (16–518). Before inclusion, 78.6% of the patients had failed to resolve subretinal fluid under mineralocorticoid receptor antagonists and 14.3% had a recurrence after half-dose photodynamic therapy. Complete resolution of subretinal fluid was observed in 42.9% at 6 months and in 53.8% at 12 months after baseline. Central retinal thickness decreased from 398 ± 135 µm to 291 ± 68 µm (p < 0.001), subfoveal choroidal thickness changed slightly (430 ± 116 µm to 419 ± 113 µm, p = 0.026), microperimetry-derived macular function improved by 19.1 ± 4.7 dB to 21.3 ± 4.8 dB (p = 0.008) and mean BCVA improved by 4.9 ± 8.6 ETDRS letters (p < 0.001). Conclusion The results show that the investigated laser treatment is effective in reducing subretinal fluid and leads to an improvement of functional parameters.

Download Full-text

Two-year follow-up of mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2018-312892 ◽

2018 ◽

Vol 103 (8) ◽

pp. 1184-1189 ◽

Cited By ~ 13

Author(s):

Marta Zola ◽

Alejandra Daruich ◽

Alexandre Matet ◽

Irmela Mantel ◽

Francine Behar-Cohen

Keyword(s):

Central Serous Chorioretinopathy ◽

Mineralocorticoid Receptor ◽

Choroidal Thickness ◽

Treatment Initiation ◽

Retinal Pigment ◽

Subretinal Fluid ◽

Chronic Central Serous Chorioretinopathy ◽

Mineralocorticoid Receptor Antagonist ◽

Subfoveal Choroidal Thickness ◽

Imaging Characteristics

AimsTo evaluate the long-term oral mineralocorticoid receptor antagonist (MRa) treatment in chronic central serous chorioretinopathy (CSC).MethodsPatients with chronic non-resolving CSC (defined as foveal subretinal fluid (SRF) lasting >4 months with retinal pigment epithelium (RPE) alterations) treated with MRa only (eplerenone or spironolactone) for at least 6 months were retrospectively included. Clinical and imaging characteristics were recorded during visits at baseline, 6, 12, 18 and 24 months.ResultsSixteen eyes of 16 patients were included (mean age 53±11 years; 14 men, 2 women). Mean duration of SRF before treatment initiation was 11.2±19.7 months. MRa treatment was administered during 21.0±5.1 months (range, 10–24 months). There was a progressive improvement of visual acuity (p=0.05), a decrease of foveal SRF height (p=0.011), central macular thickness (p=0.004) and subfoveal choroidal thickness (p=0.002) over 24 months. Changes in SRF were correlated with subfoveal choroidal thickness at 24 months (p=0.006, Spearman r=065). The mean time to complete foveal SRF resolution was 10.5±8.0 months after treatment initiation. At 24 months, foveal SRF resolution was achieved in 13 eyes (81%). Minor side effects occurred in five patients (31%) and resolved after switching between MRa.ConclusionThe visual and anatomical benefit of MRa treatment prolonged for 6 months or more in chronic, non-resolving CSC appeared to be maintained over a 24-month period. These results suggest that MRa can be proposed as an alternative therapy in severe CSC with advanced RPE alterations.

Download Full-text